恩替卡韦治疗代偿期乙肝肝硬化患者预后效果观察  

Effect of Entecavir on Prognosis of Patients with Compensated Hepatitis B Cirrhosis

作　　者：王雪刚[1] 梁锦峰 杨澍[1] 武海波 WANG Xuegang;LIANG Jinfeng;YANG Shu(Department of Infectious Diseases,Baoan People′s Hospital of Shenzhen,Shenzhen,Guangdong 518000)

机构地区：[1]深圳市宝安人民医院,广东深圳518000

出　　处：《航空航天医学杂志》2020年第8期913-915,共3页Journal of Aerospace medicine

摘　　要：目的观察恩替卡韦治疗代偿期乙肝肝硬化患者预后效果。方法选择收诊的108例代偿期乙肝肝硬化患者作为研究对象,根据随机数表法将其分成两组,设为对照组和治疗组,每组54例,对照组给予阿德福韦酯治疗,治疗组给予恩替卡韦治疗,观察评价临床疗效。结果治疗组治疗前后ALT、AST、PT、TBIL、ALB指标明显降低,经统计学分析差异有统计学意义;对照组治疗前后ALT、AST、PT、TBIL指标明显降低,经统计学分析差异有统计学意义,ALB指标增高,经统计学分析差异无统计学意义。治疗前,组间ALT、AST、PT、TBIL、ALB变化不大,无统计学差异(P>0.05),治疗后,组间差异显著,有统计学意义(P<0.05);治疗前,对照组和治疗组ALT、AST、PT、TBIL、ALB指标水平经统计学分析无差异(P>0.05);治疗后,对照组和治疗组ALT、AST、PT、TBIL、ALB指标水平显著,其中治疗组ALT、AST、PT、TBIL水平低于对照组,差异有统计学意义(P<0.05)ALB指标高于对照组,差异有统计学意义。随访发现,治疗组肝功能失代偿发生率明显低于对照组,经分析差异有统计学意义(χ~2=4.285,P<0.05)。结论相比阿德福韦酯,恩替卡韦治疗代偿期乙肝肝硬化,疗效显著,预后佳,可作为临床首选乙肝抗病毒药物。Objective To observe the effect of entecavir in the treatment of compensatory hepatitis B cirrhosis.Methods 108 patients with compensatory hepatitis B cirrhosis were selected as the research object.According to the method of random number table,they were divided into two groups:the control group and the treatment group,54 cases in each group.The control group was treated with adefovir dipivoxil,the treatment group was treated with entecavir,and the clinical effect was observed and evaluated.Results①before and after treatment,alt,AST,Pt,TBIL and ALB indexes in the treatment group were significantly lower than those in the control group.After statistical analysis,alt,AST,Pt and TBIL indexes in the control group were significantly lower than those in the control group.After statistical analysis,the differences were statistically significant,ALB indexes were higher,but there was no statistical significance.Before treatment,there was no significant difference in alt,AST,Pt,TBIL and ALB among the groups(P>0.05).After treatment,there was significant difference between the groups(P<0.05);before treatment,there was no difference in alt,AST,Pt,TBIL and ALB between the control group and the treatment group(P>0.05);after treatment,there was significant difference in alt,AST,Pt,TBIL and ALB between the control group and the treatment group The levels of alt,AST,Pt and TBIL in the treatment group were lower than those in the control group,and the difference was statistically significant(P<0.05).②The incidence of liver function decompensation in the treatment group was significantly lower than that in the control group(χ~2=4.285,P<0.05).Conclusions Compared with adefovir dipivoxil,entecavir can be used as the first antiviral drug in the treatment of compensatory hepatitis B cirrhosis.

关 键 词：恩替卡韦 代偿期 乙肝肝硬化 阿德福韦酯 

分 类 号：R575.2[医药卫生—消化系统]